CKI 7 dihydrochloride: Selective Casein Kinase 1 Inhibitor Insights

Executive Summary: CKI 7 dihydrochloride is a potent and selective ATP-competitive inhibitor of Casein kinase 1 (CK1), validated in multiple signaling contexts (product information). It is instrumental for dissecting the Wnt/β-catenin and circadian rhythm pathways in both biochemical and cell-based assays (see review). With a molecular weight of 358.67 and solubility limits defined in DMSO and water, it enables controlled experimental conditions. CKI 7 dihydrochloride is supplied by APExBIO at ≥98% purity, facilitating reproducible inhibition of CK1 in cancer biology and neurobiology research. Importantly, its use is limited to research settings and is not suitable for diagnostics or therapeutic applications.

Biological Rationale

Casein kinase 1 (CK1) is a family of serine/threonine protein kinases implicated in the regulation of diverse cellular processes, including circadian rhythm, cell cycle progression, and DNA repair. Aberrant CK1 activity is linked to tumorigenesis, metastasis, and neurodegenerative disorders (IJBiomac 2026). The Wnt/β-catenin pathway, modulated by CK1, governs cell proliferation and differentiation—dysregulation is associated with cancer progression. CK1 also phosphorylates core circadian clock proteins, modulating sleep-wake cycles and metabolic regulation. Thus, precise inhibition of CK1 provides a strategic entry point for mechanistic studies in oncology and chronobiology.

Mechanism of Action of CKI 7 dihydrochloride

CKI 7 dihydrochloride (N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide dihydrochloride) acts as a competitive inhibitor at the ATP-binding site of CK1 isoforms. This blockade prevents CK1-mediated phosphorylation of substrate proteins, such as β-catenin and PER proteins (protocol guide). The compound exhibits high selectivity, minimizing off-target kinase inhibition at typical working concentrations. This specificity enables dissection of CK1-dependent phosphorylation events in complex signaling networks.

Evidence & Benchmarks

• CKI 7 dihydrochloride inhibits CK1 activity in vitro with nanomolar-to-micromolar IC₅₀ values, depending on isoform and substrate (product data).
• In Wnt signaling studies, CK1 inhibition reduces β-catenin phosphorylation, thereby altering downstream gene expression (targeted pathway review).
• In circadian rhythm models, CKI 7 dihydrochloride modulates PER protein stability, affecting period length and phase (signaling review).
• In cancer cell lines, CK1 inhibition by CKI 7 dihydrochloride impairs proliferation and enhances apoptosis rates in a dose-dependent manner (translational insight).
• CKI 7 dihydrochloride displays solubility up to 17.93 mg/ml in DMSO and up to 7.17 mg/ml in water at room temperature (product specification).
• MAPK10/KRT16 axis studies highlight the interconnectedness of CK1 signaling with metastasis regulation in non-small cell lung cancer, suggesting synergy with CK1 inhibition strategies (IJBiomac 2026).

Applications, Limits & Misconceptions

CKI 7 dihydrochloride is integral for probing CK1-related signaling in cancer biology research, such as metastasis and cell cycle studies, and for circadian rhythm regulation studies. It is also used in apoptosis assays to clarify the role of CK1 in cell fate decisions. Standard applications include in vitro kinase assays, cell-based functional assays, and pathway mapping experiments. The compound’s robust selectivity profile makes it suitable for dissecting CK1-mediated processes without significant off-target effects at recommended concentrations (see also). However, CKI 7 dihydrochloride is not cell-type agnostic and may require empirical optimization for different models. It is not indicated for diagnostic use or clinical therapy.

Common Pitfalls or Misconceptions

• CKI 7 dihydrochloride is not a pan-kinase inhibitor; it does not broadly inhibit other serine/threonine kinases at typical working concentrations.
• It is not recommended for long-term solution storage due to stability limitations. Fresh preparation is advised (APExBIO guidance).
• Assuming results in one cancer cell type (e.g., NSCLC) directly translate to others may be misleading; context-specific pathway crosstalk must be considered.
• CKI 7 dihydrochloride is not approved for human diagnostic or therapeutic use.
• Overuse or excessive concentrations may result in non-specific effects or cytotoxicity not attributable to CK1 inhibition alone.

Workflow Integration & Parameters

Integration of CKI 7 dihydrochloride into experimental workflows requires attention to solubility, dosing, and timing. For kinase assays, use freshly prepared DMSO or aqueous solutions. For cell-based assays, titrate concentrations to identify the minimal effective dose for pathway inhibition without overt cytotoxicity. APExBIO provides both 1 mg and 5 mg packaging for flexible experimental design.

Protocol Parameters

• Stock solution preparation: Dissolve in DMSO at up to 17.93 mg/ml; store aliquots at -20°C, avoid repeated freeze-thaw cycles (APExBIO).
• Working concentration for cell assays: 1–50 μM, empirically optimized for cell type and endpoint (review).
• Kinase assay incubation: 30–60 min at 37°C; competitive with ATP, so ensure substrate and ATP levels are physiologically relevant.
• Apoptosis/cell cycle assays: Treat cells for 12–48 h, monitor viability and pathway markers (translational guidance).
• Storage: Store powder at -20°C in desiccated conditions; avoid moisture exposure.

This article extends prior protocol guides (protocol workflow) by integrating recent cancer signaling evidence and practical troubleshooting for metastasis models.

Conclusion & Outlook

CKI 7 dihydrochloride, as supplied by APExBIO, is a validated, selective Casein kinase 1 inhibitor supporting advanced research into cancer biology and circadian regulation (B4936 kit). Its mechanistic precision enables functional dissection of CK1-dependent phosphorylation, with proven utility in Wnt signaling pathway and metastasis studies. Ongoing research into the MAPK10/KRT16 axis further underscores the importance of kinase signaling context in non-small cell lung cancer (IJBiomac 2026). Future studies may refine dosage strategies and expand applications, but clinical translation remains beyond current evidence.